# RESEARCH NOTE Open Access



# Total laryngectomy and readmission: causes, rates and predictors

Almoaidbellah Rammal<sup>1</sup>, Abdulsalam Alqutub<sup>2\*</sup>, Omar Alsulami<sup>2</sup>, Naif Mozahim<sup>2</sup>, Sara Mozahim<sup>2</sup>, Mohammed Awadh<sup>2</sup>, Muatasaim Hakami<sup>1</sup>, Rahaf AlThomali<sup>1</sup> and Ahmed Mogharbel<sup>1,3</sup>

# **Abstract**

**Background** Total laryngectomy (TL) is a complex procedure, and patients undergoing TL are at high risk for readmission, which exposes them to hospital-acquired complications. Readmission rate is a metric for quality of care. We aimed to identify the rate, causes, and predictors of hospital readmission within 60 days after discharge following TL.

**Methods** This is a 12-year retrospective study where we included all patients undergoing TL in a single tertiary care center between 2008 and 2022. Patient charts were reviewed for demographics, comorbidities, and causes for readmission.

**Results** Of 83 patients who underwent TL, 12 (14.50%) were readmitted within 60 days. Common causes were surgical site infection (33.33%) and mucocutaneous fistula (25%). Significant predictors for readmission were tobacco use (P=0.003), African ethnicity (P=0.004), being unmarried (P<0.001), lower preoperative serum albumin (P<0.001), higher preoperative TSH (P=0.03), higher preoperative neutrophil count (P=0.035), higher American Society of Anesthesiology (ASA) score (P=0.028), and higher Cumulative Illness Rating Scale (CIRS) score (P=0.029).

**Conclusion** One in every seven patients were readmitted following TL. Frequent causes include wound infection and fistulas. Predictors include preoperative hypoalbuminemia, hypothyroidism, African ethnicity, being unmarried, tobacco use, and a higher baseline burden of comorbidities. Such factors can be targeted to reduce hospital readmission rates.

**Keywords** Laryngectomy, Patient readmission, Surgical wound Infection, Retrospective studies, Hypoalbuminemia, Ethnicity

# Introduction

Total laryngectomy (TL) is a widely performed surgical procedure for treating laryngeal cancer [1]. While organ preserving management of laryngeal cancer is the preferred option of treatment, TL is still indicated in patients with advanced laryngeal malignancies, a failed response to chemotherapy or radiotherapy, and histopathological subtypes, which are known to be radiotherapy resistant [2–4]. Although TL is a relatively safe procedure, it still has a fair share of surgical complications. These complications include bleeding, airway compromise, fistulas, pharyngoesophageal stenosis, stoma stenosis, and hypothyroidism [5]. Due to these complications, patients who undergo TL are always at risk of readmission, which causes a burden to the patient and the healthcare system.

\*Correspondence: Abdulsalam Alqutub ksasalam47@hotmail.com

<sup>1</sup> Otolaryngology–Head and Neck Surgery Department, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia

<sup>&</sup>lt;sup>3</sup> Otolaryngology-Head and Neck Surgery Department, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>&</sup>lt;sup>2</sup> Otolaryngology–Head and Neck Surgery Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

Rammal et al. BMC Research Notes (2023) 16:377 Page 2 of 5

A single institution retrospective study conducted at an academic hospital found that patients who underwent TL were 4.7 times more likely to be admitted than other head and neck surgeries [6]. Published works regarding the rate of readmissions after laryngectomy ranged from 10.9 to 20.6%, with postoperative pharyngocutaneous fistula and postoperative infection as the most common cause of readmission [7-12]. Even with studies on the risk factors and problems that lead to readmission after laryngectomy, the rationale for the high readmission percentage in contrast to other head and neck surgeries remains unknown. Moreover, the rates and risk factors for readmission after laryngectomy need to be clearly described in the Saudi population. This study aims to determine the incidence, risk factors, and most likely complications that will cause readmission following laryngectomy within 60 days of hospital discharge at King Abdulaziz University Hospital in Jeddah, Saudi Arabia.

# **Methods**

After receiving ethical approval from the Institutional Review Board (IRB), we reviewed the records of patients who underwent TL between 2008 and 2022.

The causes of readmission were extracted as the final diagnosis from the medical record system. Only the first episode of unplanned returns was acquired if more than one episode was identified within the first 60 days after discharge.

We included all patients who underwent TL in our center between 2008 and 2022. Patients with significant missing data, such as not having any recorded causes for readmission were excluded from the study.

Demographic data such as age, gender and race, marital status, tobacco use, dates of first admission, discharge, and return were also gathered.

The records of the patients were also reviewed for any incidents that occurred before or during their initial hospitalization, such as any history of tracheostomy, intubation, or intensive care unit (ICU) admission. We also reviewed the records for any history of chemotherapy or radiotherapy.

Additionally, preoperative thyroid stimulating hormone (TSH), serum albumin, white blood cell count, platelets, and hemoglobin were collected.

The Cumulative Illness Rating Scale (CIRS) and the American Society of Anesthesiology (ASA) score were used to assess the patient's comorbidities. The CIRS is a comorbidity scale that analyzes the disease burden across 13 body systems [13].

The data were entered into Google Forms and then exported to Excel 16.0. Statistical analysis was performed using the Statistical Package for the Social Sciences for Windows version 21.0 (IBM SPSS Statistics), with

statistical significance set at P 0.05. Continuous variables are expressed as the means and standard deviations (SD) or median with interquartile ranges (IQR) depending on the distribution. Categorical variables are summarized using numbers and frequencies. Student's t test was performed to compare means. The Mann–Whitney U test was used to compare medians, while the chi-square test was used to compare frequencies. Variables with significant relationships in univariate analysis were employed in multivariate analysis.

### Results

Eighty-three cases met the study criteria, of which 12 (14.50%) were readmitted within 60 days after discharge. The mean time to hospital readmission was  $26.66 \pm 11.06$  days (range 1–58 days). Table 1 shows the causes of readmission; the most common reason was surgical site infection (33.33%), followed by mucocutaneous fistula (25%).

Significant predictors for unplanned readmission included tobacco use (P=0.008), African ethnicity (P=0.017), and being unmarried, separated, or widowed (P<0.001). Lower preoperative serum albumin levels (10.5 vs. 23.83 g/L, P<0.001), higher preoperative TSH levels (13.03 vs. 2.16 mIU/L, P = 0.031), and higher preoperative neutrophil count (5.87 vs. 4.01 K/µL, P=0.037) showed significant associations with readmission within 60 days after discharge. Additionally, having a higher baseline burden of disease when using the ASA score (P < 0.001) and the CIRS score (P = 0.028) was shown to be a significant predictor for hospital readmission. A simple linear regression between the two scores revealed a significant positive correlation (p < 0.001), with a  $r^2$  = 0.409. Table 2 summarizes the characteristics of patients who underwent TL and compares readmitted and nonreadmitted patients after hospital discharge.

The multivariate logistic regression analysis revealed significant risk factors for readmission after hospital discharge, including history of tobacco use [odds ratio (OR) = 0.24; 95% confidence interval (CI) 0.08–0.39; P = 0.003], African ethnicity (OR = 0.14; 95% CI 0.05–0.23; P = 0.004), being unmarried, separated, or widowed

Table 1 Rate and causes of readmission

Causes	Numbers	Rates (%)
Surgical site infection	4	33.33
Mucocutaneous fistula	3	25
Dysphagia	2	16.67
Equipment issues: tracheostomy, surgical drain	1	8.33
Stomal stenosis	1	8.33
Dyspnea	1	8.33

Rammal et al. BMC Research Notes (2023) 16:377 Page 3 of 5

**Table 2** Comparison between readmitted and nonreadmitted patients in gender, age, ethnicity, marital status, tobacco use, ASA score, and CIRS score, history of intubation, ICU admission, chemotherapy, radiotherapy, preoperative TSH, serum albumin, white blood cells, neutrophils, lymphocytes, and hemoglobin

Gender (n, %)  Male 9 (75) 52 (73.20) 0.351  Female 3 (25) 19 (26.80)  Age  Mean (SD) 50.9 (18.55) 51.5 (6.74) 0.913  Ethnicity (n, %)  Arab 1 (8.30) 25 (35.20) 0.017  Asian 3 (25) 29 (40.80)  African 8 (66.70) 17 (23.90)  Marital status (n, %)  Married 2 (16.70) 69 (97.20) <0.001  Ulmarried (single, divorced, separated)  ASA  Mean (SD) 3.75 (2.30) 2.3 (0.92) <0.001  CIRS  Mean (SD) 9 (5.61) 5.58 (4.80) 0.028  Chemotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 35 (49.30)  Chemotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30) 0.516	Variable	Readmitted	Nonreadmitted	P value	
Female         3 (25)         19 (26.80)           Age           Mean (SD)         50.9 (18.55)         51.5 (6.74)         0.913           Ethnicity (n, %)         Arab         1 (8.30)         25 (35.20)         0.017           Asian         3 (25)         29 (40.80)         African         8 (66.70)         17 (23.90)           Marital         8 (66.70)         17 (23.90)         40.001           Married         2 (16.70)         69 (97.20)         < 0.001           Unmarried (single, divorced, separated)         10 (83.30)         2 (2.80)            ASA         Mean (SD)         3.75 (2.30)         2.3 (0.92)         < 0.001           CIRS         Mean (SD)         9 (5.61)         5.58 (4.80)         0.028           Chemotherapy and/or radiotherapy (n, %)         Chemotherapy and/or radiotherapy (n, %)         6 (50)         20 (28.20)         0.028           Chemotherapy (n, %)         1 (8.33)         8 (11.30)         0.516         6.66         6.66         7.6 (28.20)         0.028           Radiotherapy (n, %)         1 (8.33)         8 (11.30)         0.028         6.61         6.60         9.00         1.02         1.02         1.02         1.02         1.02         1.02         <	Gender (n, %)				
Age         Mean (SD)         50.9 (18.55)         51.5 (6.74)         0.913           Ethnicity (n, %)         Arab         1 (8.30)         25 (35.20)         0.017           Asian         3 (25)         29 (40.80)         African         8 (66.70)         17 (23.90)           Marital status (n, %)         4 (66.70)         17 (23.90)         4 (0.00)         4 (0.00)           Married         2 (16.70)         69 (97.20)         < 0.001	Male	9 (75)	52 (73.20)	0.351	
Mean (SD)         50.9 (18.55)         51.5 (6.74)         0.913           Ethnicity (n, %)         Arab         1 (8.30)         25 (35.20)         0.017           Asian         3 (25)         29 (40.80)         African         8 (66.70)         17 (23.90)           Marital status (n, %)         Married         2 (16.70)         69 (97.20)         <0.001	Female	3 (25)	19 (26.80)		
Ethnicity (n, %)  Arab	Age				
Arab		50.9 (18.55)	51.5 (6.74)	0.913	
Arab					
African       8 (66.70)       17 (23.90)         Married       2 (16.70)       69 (97.20)       < 0.001         Unmarried (single, divorced, separated)       10 (83.30)       2 (2.80)         ASA       Mean (SD)       3.75 (2.30)       2.3 (0.92)       < 0.001         CIRS       Mean (SD)       9 (5.61)       5.58 (4.80)       0.028         Chemotherapy and/or radiotherapy (n,%)       Chemotherapy and/or radiotherapy (n,%)       6 (50)       20 (28.20)       0.516         Radiotherapy       1 (8.33)       8 (11.30)       0.516         Radiotherapy       6 (50)       20 (28.20)       0.001         Neither       4 (33.33)       35 (49.30)       0.008         Tobacco use       Yes       12 (100)       39 (54.90)       0.008         No       0 (0)       32 (45.10)       0.001         ICU admission (n, %)       Yes       9 (75)       52 (73.20)       0.351         No       3 (25)       19 (26.80)       0.001         Intubation (n, %)       Yes       8 (66.67)       52 (73.20)       0.351         No       4 (33.33)       19 (26.80)       0.001         Preoperative TSH (mIU/L)       Mean (SD)       13.03 (9.22)       2.16 (0.82)       0	Arab	1 (8.30)	25 (35.20)	0.017	
Marital status (n, %)  Married 2 (16.70) 69 (97.20) <0.001  Unmarried (single, divorced, separated)  ASA  Mean (SD) 3.75 (2.30) 2.3 (0.92) <0.001  CIRS  Mean (SD) 9 (5.61) 5.58 (4.80) 0.028  Chemotherapy and/or radiotherapy (n, %)  Chemotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 6 (50) 20 (28.20) Neither 4 (33.33) 35 (49.30)  Tobacco use  Yes 12 (100) 39 (54.90) 0.008  No 0 (0) 32 (45.10)  ICU admission (n, %)  Yes 9 (75) 52 (73.20) 0.351  No 3 (25) 19 (26.80)  Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative albumin (g/L)  Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/μL)  Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/μL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/μL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/μL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)	Asian	3 (25)	29 (40.80)		
Married (single, divorced, separated)  ASA  Mean (SD) 3.75 (2.30) 2.3 (0.92) <0.001  CIRS  Mean (SD) 9 (5.61) 5.58 (4.80) 0.028  Chemotherapy and/or radiotherapy (n, %)  Chemotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 6 (50) 20 (28.20) Neither 4 (33.33) 35 (49.30)  Tobacco use  Yes 12 (100) 39 (54.90) 0.008  No 0 (0) 32 (45.10)  ICU admission (n, %)  Yes 9 (75) 52 (73.20) 0.351  No 3 (25) 19 (26.80)  Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative albumin (g/L)  Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/µL)  Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/µL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)	African	8 (66.70)	17 (23.90)		
Unmarried (single, divorced, separated)  ASA  Mean (SD) 3.75 (2.30) 2.3 (0.92) <0.001  CIRS  Mean (SD) 9 (5.61) 5.58 (4.80) 0.028  Chemotherapy and/or radiotherapy (n, %)  Chemotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 6 (50) 20 (28.20) 0.000  Neither 4 (33.33) 35 (49.30)  Tobacco use  Yes 12 (100) 39 (54.90) 0.008  No 0 (0) 32 (45.10)  ICU admission (n, %)  Yes 9 (75) 52 (73.20) 0.351  No 3 (25) 19 (26.80)  Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative albumin (g/L)  Mean (SD) 10.5 (7.88) 23.92 (9.15) <0.001  Preoperative white blood cell count (K/µL)  Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/µL)  Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/µL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)	Marital status (n, %)				
Unmarried (single, divorced, separated)  ASA  Mean (SD) 3.75 (2.30) 2.3 (0.92) <0.001  CIRS  Mean (SD) 9 (5.61) 5.58 (4.80) 0.028  Chemotherapy and/or radiotherapy (n, %)  Chemotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30)  Chemoradiotherapy 6 (50) 20 (28.20)  Neither 4 (33.33) 35 (49.30)  Tobacco use  Yes 12 (100) 39 (54.90) 0.008  No 0 (0) 32 (45.10)  ICU admission (n, %)  Yes 9 (75) 52 (73.20) 0.351  No 3 (25) 19 (26.80)  Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative white blood cell count (K/µL)  Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/µL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)	Married	2 (16.70)	69 (97.20)	< 0.001	
ASA  Mean (SD) 3.75 (2.30) 2.3 (0.92) <0.001  CIRS  Mean (SD) 9 (5.61) 5.58 (4.80) 0.028  Chemotherapy and/or radiotherapy (n, %)  Chemotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30)  Chemoradiotherapy 6 (50) 20 (28.20)  Neither 4 (33.33) 35 (49.30)  Tobacco use  Yes 12 (100) 39 (54.90) 0.008  No 0 (0) 32 (45.10)  ICU admission (n, %)  Yes 9 (75) 52 (73.20) 0.351  No 3 (25) 19 (26.80)  Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative albumin (g/L)  Mean (SD) 10.5 (7.88) 23.92 (9.15) <0.001  Preoperative neutrophil count (K/µL)  Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/µL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)	Unmarried (single, divorced, separated)				
CIRS  Mean (SD) 9 (5.61) 5.58 (4.80) 0.028  Chemotherapy and/or radiotherapy (n, %)  Chemotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30)  Chemoradiotherapy 6 (50) 20 (28.20)  Neither 4 (33.33) 35 (49.30)  Tobacco use  Yes 12 (100) 39 (54.90) 0.008  No 0 (0) 32 (45.10)  ICU admission (n, %)  Yes 9 (75) 52 (73.20) 0.351  No 3 (25) 19 (26.80)  Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative albumin (g/L)  Mean (SD) 10.5 (7.88) 23.92 (9.15) <0.001  Preoperative white blood cell count (K/µL)  Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/µL)  Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/µL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)					
CIRS  Mean (SD) 9 (5.61) 5.58 (4.80) 0.028  Chemotherapy and/or radiotherapy (n, %)  Chemotherapy 1 (8.33) 8 (11.30) 0.516  Radiotherapy 1 (8.33) 8 (11.30)  Chemoradiotherapy 6 (50) 20 (28.20)  Neither 4 (33.33) 35 (49.30)  Tobacco use  Yes 12 (100) 39 (54.90) 0.008  No 0 (0) 32 (45.10)  ICU admission (n, %)  Yes 9 (75) 52 (73.20) 0.351  No 3 (25) 19 (26.80)  Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative albumin (g/L)  Mean (SD) 10.5 (7.88) 23.92 (9.15) <0.001  Preoperative white blood cell count (K/µL)  Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/µL)  Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/µL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)	Mean (SD)	3.75 (2.30)	2.3 (0.92)	< 0.001	
Chemotherapy         1 (8.33)         8 (11.30)         0.516           Radiotherapy         1 (8.33)         8 (11.30)         0.516           Radiotherapy         1 (8.33)         8 (11.30)         0.516           Radiotherapy         6 (50)         20 (28.20)         0.008           Neither         4 (33.33)         35 (49.30)         0.008           No         0 (0)         32 (45.10)         0.008           No         0 (0)         32 (45.10)         0.008           No         0 (0)         32 (45.10)         0.351           No         3 (25)         19 (26.80)         0.351           No         3 (25)         19 (26.80)         0.351           No         4 (33.33)         19 (26.80)         0.031           Preoperative TSH (mIU/L)         Mean (SD)         13.03 (9.22)         2.16 (0.82)         0.031           Preoperative white blood cell count (K/μL)         Mean (SD)	CIRS				
Chemotherapy       1 (8.33)       8 (11.30)       0.516         Radiotherapy       1 (8.33)       8 (11.30)       0.516         Radiotherapy       6 (50)       20 (28.20)       0.008         Neither       4 (33.33)       35 (49.30)       0.008         Tobacco use       Yes       12 (100)       39 (54.90)       0.008         No       0 (0)       32 (45.10)       0.008         No       9 (75)       52 (73.20)       0.351         No       3 (25)       19 (26.80)         Intubation (n, %)       Yes       8 (66.67)       52 (73.20)       0.351         No       4 (33.33)       19 (26.80)         Preoperative TSH (mIU/L)       Mean (SD)       13.03 (9.22)       2.16 (0.82)       0.031         Preoperative albumin (g/L)       Mean (SD)       10.5 (7.88)       23.92 (9.15)       <0.001	Mean (SD)	9 (5.61)	5.58 (4.80)	0.028	
Radiotherapy 1 (8.33) 8 (11.30) Chemoradiotherapy 6 (50) 20 (28.20) Neither 4 (33.33) 35 (49.30) Tobacco use Yes 12 (100) 39 (54.90) 0.008 No 0 (0) 32 (45.10)  ICU admission (n, %) Yes 9 (75) 52 (73.20) 0.351 No 3 (25) 19 (26.80)  Intubation (n, %) Yes 8 (66.67) 52 (73.20) 0.351 No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L) Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative white blood cell count (K/μL) Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/μL) Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/μL) Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/μL) Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)					
Radiotherapy 1 (8.33) 8 (11.30) Chemoradiotherapy 6 (50) 20 (28.20) Neither 4 (33.33) 35 (49.30) Tobacco use Yes 12 (100) 39 (54.90) 0.008 No 0 (0) 32 (45.10)  ICU admission (n, %) Yes 9 (75) 52 (73.20) 0.351 No 3 (25) 19 (26.80)  Intubation (n, %) Yes 8 (66.67) 52 (73.20) 0.351 No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L) Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative white blood cell count (K/μL) Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/μL) Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/μL) Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/μL) Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)			8 (11.30)	0.516	
Chemoradiotherapy         6 (50)         20 (28.20)           Neither         4 (33.33)         35 (49.30)           Tobacco use         Yes         12 (100)         39 (54.90)         0.008           No         0 (0)         32 (45.10)         0.351           ICU admission (n, %)         Yes         9 (75)         52 (73.20)         0.351           No         3 (25)         19 (26.80)         0.351           No         4 (33.33)         19 (26.80)         0.351           No         4 (33.33)         19 (26.80)         0.351           Preoperative TSH (mlU/L)         Mean (SD)         13.03 (9.22)         2.16 (0.82)         0.031           Preoperative albumin (g/L)         Mean (SD)         10.5 (7.88)         23.92 (9.15)         <0.001		1 (8.33)			
Neither 4 (33.33) 35 (49.30)  Tobacco use Yes 12 (100) 39 (54.90) 0.008 No 0 (0) 32 (45.10)  ICU admission (n, %) Yes 9 (75) 52 (73.20) 0.351 No 3 (25) 19 (26.80)  Intubation (n, %) Yes 8 (66.67) 52 (73.20) 0.351 No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L) Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative white blood cell count (K/µL) Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/µL) Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/µL) Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/µL) Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)					
Tobacco use Yes 12 (100) 39 (54.90) 0.008 No 0 (0) 32 (45.10)  ICU admission (n, %) Yes 9 (75) 52 (73.20) 0.351 No 3 (25) 19 (26.80)  Intubation (n, %) Yes 8 (66.67) 52 (73.20) 0.351 No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L) Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative white blood cell count (K/μL) Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/μL) Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/μL) Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/μL) Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)	Neither	4 (33.33)	35 (49.30)		
No 0 (0) 32 (45.10)  ICU admission (n, %)  Yes 9 (75) 52 (73.20) 0.351  No 3 (25) 19 (26.80)  Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative albumin (g/L)  Mean (SD) 10.5 (7.88) 23.92 (9.15) <0.001  Preoperative white blood cell count (K/μL)  Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/μL)  Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/μL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/μL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)	Tobacco use	(	,		
No 0 (0) 32 (45.10)  ICU admission (n, %)  Yes 9 (75) 52 (73.20) 0.351  No 3 (25) 19 (26.80)  Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative albumin (g/L)  Mean (SD) 10.5 (7.88) 23.92 (9.15) <0.001  Preoperative white blood cell count (K/μL)  Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/μL)  Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/μL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/μL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)	Yes	12 (100)	39 (54.90)	0.008	
ICU admission (n, %)         Yes       9 (75)       52 (73.20)       0.351         No       3 (25)       19 (26.80)         Intubation (n, %)       Yes       8 (66.67)       52 (73.20)       0.351         No       4 (33.33)       19 (26.80)         Preoperative TSH (mIU/L)       Mean (SD)       13.03 (9.22)       2.16 (0.82)       0.031         Preoperative albumin (g/L)       Mean (SD)       10.5 (7.88)       23.92 (9.15)       <0.001	No	0 (0)	32 (45.10)		
Yes         9 (75)         52 (73.20)         0.351           No         3 (25)         19 (26.80)           Intubation (n, %)         Yes         8 (66.67)         52 (73.20)         0.351           No         4 (33.33)         19 (26.80)           Preoperative TSH (mIU/L)         Mean (SD)         13.03 (9.22)         2.16 (0.82)         0.031           Preoperative albumin (g/L)         Mean (SD)         10.5 (7.88)         23.92 (9.15)         <0.001	ICU admission (n, %)				
No 3 (25) 19 (26.80) Intubation (n, %)  Yes 8 (66.67) 52 (73.20) 0.351  No 4 (33.33) 19 (26.80)  Preoperative TSH (mIU/L)  Mean (SD) 13.03 (9.22) 2.16 (0.82) 0.031  Preoperative albumin (g/L)  Mean (SD) 10.5 (7.88) 23.92 (9.15) <0.001  Preoperative white blood cell count (K/μL)  Mean (SD) 9.19 (3.46) 7.6 (2.65) 0.068  Preoperative neutrophil count (K/μL)  Mean (SD) 5.87 (4.03) 4.01 (2.52) 0.035  Preoperative platelet count (K/μL)  Mean (SD) 351.833 (138.49) 295.92 (100.07) 0.095  Preoperative lymphocyte count (K/μL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)		9 (75)	52 (73.20)	0.351	
Intubation (n, %)         Yes       8 (66.67)       52 (73.20)       0.351         No       4 (33.33)       19 (26.80)         Preoperative TSH (mIU/L)         Mean (SD)       13.03 (9.22)       2.16 (0.82)       0.031         Preoperative albumin (g/L)         Mean (SD)       10.5 (7.88)       23.92 (9.15)       <0.001	No				
Yes         8 (66.67)         52 (73.20)         0.351           No         4 (33.33)         19 (26.80)           Preoperative TSH (mIU/L)         Verify (0.82)         0.031           Preoperative albumin (g/L)         Verify (0.82)         0.031           Preoperative albumin (g/L)         Verify (0.82)         0.001           Preoperative white blood cell count (K/μL)         Verify (0.65)         0.068           Preoperative neutrophil count (K/μL)         Verify (0.82)         0.035           Preoperative platelet count (K/μL)         Verify (0.84)         Verify (0.84)         0.095           Preoperative lymphocyte count (K/μL)         Verify (0.84)         Verify (0.84)         0.01           Preoperative lymphocyte count (K/μL)         Verify (0.84)         Verify (0.84)         0.061           Hemoglobin (g/dL)         Verify (0.82)         0.035         0.612	Intubation (n. %)		,		
No         4 (33.33)         19 (26.80)           Preoperative TSH (mIU/L)         Mean (SD)         13.03 (9.22)         2.16 (0.82)         0.031           Preoperative albumin (g/L)         Mean (SD)         10.5 (7.88)         23.92 (9.15)         <0.001		8 (66.67)	52 (73.20)	0.351	
Preoperative TSH (mIU/L)         Mean (SD)       13.03 (9.22)       2.16 (0.82)       0.031         Preoperative albumin (g/L)       0.001       0.001       0.001         Preoperative white blood cell count (K/μL)       0.001       0.001       0.001         Preoperative neutrophil count (K/μL)       0.001       0.001       0.001       0.001         Preoperative neutrophil count (K/μL)       0.001 <td></td> <td></td> <td></td> <td>0.55</td>				0.55	
Mean (SD)       13.03 (9.22)       2.16 (0.82)       0.031         Preoperative albumin (g/L)       (G.82)       0.001         Mean (SD)       10.5 (7.88)       23.92 (9.15)       <0.001			(		
Preoperative albumin (g/L)         Mean (SD)       10.5 (7.88)       23.92 (9.15)       <0.001			2.16 (0.82)	0.031	
Mean (SD)       10.5 (7.88)       23.92 (9.15)       <0.001         Preoperative white blood cell count (K/μL)       3.19 (3.46)       7.6 (2.65)       0.068         Preoperative neutrophil count (K/μL)       4.01 (2.52)       0.035         Preoperative platelet count (K/μL)       4.01 (2.52)       0.035         Preoperative platelet count (K/μL)       4.01 (2.52)       0.035         Preoperative lymphocyte count (K/μL)       295.92 (100.07)       0.095         Preoperative lymphocyte count (K/μL)       4.01 (2.52)       0.035         Mean (SD)       1.84 (1.07)       2.05 (1.33)       0.612         Hemoglobin (g/dL)       1.84 (1.07)       2.05 (1.33)       0.612	, ,				
Preoperative white blood cell count (Κ/μL)         Mean (SD)       9.19 (3.46)       7.6 (2.65)       0.068         Preoperative neutrophil count (Κ/μL)       4.01 (2.52)       0.035         Preoperative platelet count (Κ/μL)       4.01 (2.52)       0.035         Preoperative platelet count (Κ/μL)       295.92 (100.07)       0.095         Preoperative lymphocyte count (Κ/μL)       4.01 (2.52)       0.035         Mean (SD)       351.833 (138.49)       295.92 (100.07)       0.095         Mean (SD)       1.84 (1.07)       2.05 (1.33)       0.612         Hemoglobin (g/dL)			23 92 (9 15)	< 0.001	
Mean (SD)       9.19 (3.46)       7.6 (2.65)       0.068         Preoperative neutrophil count (K/μL)       0.035       4.01 (2.52)       0.035         Preoperative platelet count (K/μL)       0.035       0.035       0.035         Mean (SD)       351.833 (138.49)       295.92 (100.07)       0.095         Preoperative lymphocyte count (K/μL)       0.035       0.035         Mean (SD)       1.84 (1.07)       2.05 (1.33)       0.0612         Hemoglobin (g/dL)       0.035       0.035       0.035			23.72 (3.13)	(0.001	
Preoperative neutrophil count (Κ/μL)         Mean (SD)       5.87 (4.03)       4.01 (2.52)       0.035         Preoperative platelet count (Κ/μL)       0.095       0.095         Mean (SD)       351.833 (138.49)       295.92 (100.07)       0.095         Preoperative lymphocyte count (Κ/μL)       0.612         Mean (SD)       1.84 (1.07)       2.05 (1.33)       0.612         Hemoglobin (g/dL)			76 (265)	0.068	
Mean (SD)       5.87 (4.03)       4.01 (2.52)       0.035         Preoperative platelet count (K/μL)       0.035       0.035         Mean (SD)       351.833 (138.49)       295.92 (100.07)       0.095         Preoperative lymphocyte count (K/μL)       0.612         Mean (SD)       1.84 (1.07)       2.05 (1.33)       0.612         Hemoglobin (g/dL)			7.0 (2.03)	0.000	
Preoperative platelet count (Κ/μL)         Mean (SD)       351.833 (138.49)       295.92 (100.07)       0.095         Preoperative lymphocyte count (Κ/μL)         Mean (SD)       1.84 (1.07)       2.05 (1.33)       0.612         Hemoglobin (g/dL)			4 01 (2 52)	0.035	
Mean (SD)       351.833 (138.49)       295.92 (100.07)       0.095         Preoperative lymphocyte count (K/μL)       40.07       0.000       0.000         Mean (SD)       1.84 (1.07)       0.000       0.000       0.000         Hemoglobin (g/dL)       0.000			1.01 (2.32)	0.000	
Preoperative lymphocyte count (K/µL)  Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612  Hemoglobin (g/dL)			295 92 (100 07)	0.005	
Mean (SD) 1.84 (1.07) 2.05 (1.33) 0.612 Hemoglobin (g/dL)		, ,	273.72 (100.07)	0.053	
Hemoglobin (g/dL)			2.05 (1.33)	0.612	
		1.04 (1.07)	(۱.۵۵) دی.۷	0.012	
ועבאון (עבי) 12.00 (1.49) איז און איז (עבי) 12.00 (1.49) איז (עבי) וויפוווי		12.93 /1.40\	12 //2 /1 02\	0.612	
	ואובמוז (אט)	12.03 (1.49)	12.72 (1.03)	0.012	

(OR=0.83; 95% CI 0.71–0.96; P<0.001), lower preoperative serum albumin (OR=0.51; 95% CI 0.34–0.67; P<0.001), higher preoperative TSH (OR=0.05; 95% CI 0.01–0.10; P=0.03), higher preoperative neutrophil count (OR=0.03; 95% CI 0.002–0.06; P=0.035), higher ASA score (OR=0.11; 95% CI 0.05–0.16; P=0.028), and higher CIRS score (OR=0.02; 95% CI 0.002–0.03; P=0.029).

### Discussion

We present exclusive and distinct data about the causes of unexpected hospital readmission by extending the analysis period to 60 days rather than the traditional 30 days following surgery. Our study was conducted in a tertiary referral center in western Saudi Arabia; many cases are sent to our hospital from remote regions, and transportation and referral may interfere with early follow-ups. Thus, extending the study period to 60 days after discharge would enable us to understand better the actual rate of unexpected hospital readmission following TL.

In our study, the rate of unplanned hospital return after TL was 14.50%. This is higher than the readmission rates reported in other studies. Wu et al. reported a rate of 3.20% after head and neck surgeries [14]. Graboyes et al. identified a readmission rate of 7.30% for all otolaryngological procedures [11]. Conversely, Chaudhary et al. reported a rate of 14.10% after laryngeal and oropharyngeal cancer surgery [15]. Together with our study, these reports support that the readmission rates after laryngeal surgery are higher than those after other otolaryngological procedures. Our results of increased readmission rates following laryngeal cancer surgery may be attributable to the surgery's greater complexity and the patients' complexity compared to patients undergoing other otolaryngological procedures.

Although readmission rates have been employed as a quality metric for hospital care, their use has limitations. While there are potentially preventable reasons and risk factors for readmission, nonmodifiable factors can contribute to patient readmission, including socioeconomic status, race, age, and gender [16]. In our study, patients of African descent were more likely to be readmitted after hospital discharge. It has been reported that people of African ethnicity, rather than other races, are at increased risk of prolonged hospital stay, increased readmission rates, morbidity, and mortality [8, 17–19]. It is unclear why these racial disparities exist; however, previous literature suggests that African patients are more likely to present with advanced-stage disease, tobacco use, complicated comorbidities, and lack of access to healthcare, leading to poorer outcomes [8, 20]. All patient demographics Rammal et al. BMC Research Notes (2023) 16:377 Page 4 of 5

must have adequate preoperative access to healthcare, yet traditionally underserved populations need special attention.

We found that a lower serum albumin level significantly predicts hospital return. Another study demonstrated that preoperative hypoalbuminemia is associated with higher morbidity, mortality, and postoperative complications, especially infections [21, 22]. Our study showed consistent results, as surgical site infection was the most common cause of hospital readmission after TL. In acute sickness and injury, serum albumin levels fall as the liver shifts the priority of protein synthesis from visceral proteins to acute-phase reactant proteins [23–25]. Thus, hypoalbuminemia may serve as a diagnostic tool for underlying systemic immunoinflammation.

Our study found that a higher preoperative TSH level is a risk factor for hospital readmission. Previous studies confirmed that operating on patients with overt or biochemical hypothyroidism is associated with adverse outcomes and prolonged hospital stays [26, 27].

Our study showed that patients who were unmarried, separated, or widowed were more prone to readmission. This finding aligns with other studies that revealed an association between social support and acute care needs. Wachtel et al. proved that spousal support, rather than any other family members, is a significant protective factor against unplanned hospital return after discharge [28]. Another study on patients undergoing laryngeal and oropharyngeal cancer surgery found that separation or divorce is an independent risk factor for hospital readmission [15]. These findings suggest that there is a high-risk population that should be targeted to produce interventions that prevent unplanned readmission after hospital discharge.

This study used two validated comorbidity scores to evaluate patients' comorbidities and their predictive value for readmission after TL. Both scores were significant predictors of readmission within 60 days of discharge. Previous reports confirmed that the ASA score is closely linked to predicting readmissions and is positively associated with increased readmission rates [14, 29, 30]. Additionally, the CIRS comorbidity score has been previously used in head and neck cancer patients, with higher scores suggesting worsening baseline health [13, 14, 31]. It is well-recognized that patients with head and neck cancer have more comorbidities due to long-term exposure to risk factors such as tobacco use [32, 33]. More extensive and close postsurgery follow-ups for individuals with high baseline health burdens may reduce unplanned readmissions.

# Limitations

Our findings are to be interpreted with several limitations in mind. The usual concern for retrospective studies is obtaining reliable and conclusive data on the specific cause and time of hospital return postdischarge. For the same reason, it was challenging to collect other important variables such as the stage and type of laryngeal cancer, that may have impacted the results of our study. Other limitations were multiplicity of surgeons and variable expertise which are important predictors of outcomes. The fact that our study was limited to a single area may limit the generalizability of our findings. Further multicenter prospective research activities with extended follow-up periods in larger populations are thus desired.

# Conclusion

The rate of readmission after total laryngectomy was 14.50%. Common causes were wound infection and mucocutaneous fistula. Significant predictors include preoperative hypoalbuminemia, biochemical hypothyroidism, African ethnicity, being unmarried, tobacco use, and having a higher baseline burden of comorbidities. Such causes and risk factors can be targeted to reduce hospital readmission rates.

### **Abbreviations**

TL Total laryngectomy

ASA American Society of Anesthesiology CIRS Cumulative Illness Rating Scale

TSH Thyroid stimulating hormone

ICU Intensive care unit SD Standard deviation

# Acknowledgements

The authors acknowledge the permission granted by other consultants to enroll their patients into the study.

### **Author contributions**

Conceptualization: MR, AA and RA; methodology: AA, NM, and OA; software: SM, NM, MH, and MA; validation: AA, MR, and AM; formal analysis: AA, RA, and AM; investigation: MA, and MH; resources: SM, and NM; data curation: OA; writing—original draft preparation: AA, NM, SM, OA, MR, and MA; writing—review and editing: AA, and MA; visualization: SM; supervision: ME, and AA; project administration, MR. All authors have read and agreed to publish the current version of the manuscript.

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### Availability of data and materials

Data were collected throughout the years 2022 and 2023 from the hospital's Phoenix system and patients' paper-based records and can be provided upon request for appropriate reasons.

# **Declarations**

# Ethics approval and consent to participate

All patients signed an informed written consent for their contribution to research (collecting and publishing data) prior to any data collection. The study was approved by the Biomedical Ethics Research Committee at King

Rammal et al. BMC Research Notes (2023) 16:377 Page 5 of 5

Abdulaziz University, Jeddah, Saudi Arabia, and was conducted in accordance with the ethical standards of the Declaration of Helsinki.

# Consent for publication

Not applicable.

### **Competing interests**

The authors declare no competing interests.

Received: 9 October 2023 Accepted: 29 November 2023 Published online: 20 December 2023

### References

- Chotipanich A. Total laryngectomy: a review of surgical techniques. Cureus. 2021;13(9):e18181.
- Bhattacharyya T, Kainickal CT. Current status of organ preservation in carcinoma larynx. World J Oncol. 2018;9(2):39–45. https://doi.org/10.14740/ wion1105w.
- Induction Chemotherapy plus Radiation. Compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685–90.
- Verma SP, Mahboubi H. The changing landscape of total laryngectomy surgery. Otolaryngol Head Neck Surg. 2014;150(3):413–8.
- Leong S, Kartha S-S, Kathan C, Sharp J, Mortimore S. Outcomes following total laryngectomy for squamous cell carcinoma: one centre experience. Eur Ann Otorhinolaryngol Head Neck Dis. 2012;129(6):302–7.
- Graboyes EM, Liou T-N, Kallogjeri D, Nussenbaum B, Diaz JA. Risk factors for unplanned hospital readmission in otolaryngology patients. Otolaryngol Head Neck Surg. 2013;149(4):562–71.
- Ferrandino R, Garneau J, Roof S, Pacheco C, Poojary P, Saha A, et al. The national landscape of unplanned 30-day readmissions after total laryngectomy. Laryngoscope. 2018;128(8):1842–50.
- Helman SN, Brant JA, Moubayed SP, Newman JG, Cannady SB, Chai RL. Predictors of length of stay, reoperation, and readmission following total laryngectomy. Laryngoscope. 2017;127(6):1339–44.
- Goepfert RP, Hutcheson KA, Lewin JS, Desai NG, Zafereo ME, Hessel AC, et al. Complications, hospital length of stay, and readmission after total laryngectomy. Cancer. 2017;123(10):1760–7.
- Filimonov A, Brady JS, Govindan A, Merchant A, Eloy JA, Baredes S, et al. Postoperative complications of total laryngectomy in diabetic patients. Laryngoscope. 2017;127(10):2247.
- Graboyes EM, Yang Z, Kallogjeri D, Diaz JA, Nussenbaum B. Patients undergoing total laryngectomy: an at-risk population for 30-day unplanned readmission. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1157–65.
- Shenson JA, Craig JN, Rohde SL. Effect of preoperative counseling on hospital length of stay and readmissions after total laryngectomy. Otolaryngol Head Neck Surg. 2017;156(2):289–98.
- 13. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622–6.
- Wu V, Hall SF. Rates and causes of 30-day readmission and emergency room utilization following head and neck surgery. J Otolaryngol Head Neck Surg. 2018;47(1):36. https://doi.org/10.1186/s40463-018-0283-x.
- Chaudhary H, Stewart CM, Webster K, Herbert RJ, Frick KD, Eisele DW, et al. Readmission following primary surgery for larynx and oropharynx cancer in the elderly. Laryngoscope. 2017;127(3):631–41.
- Benbassat J, Taragin M. Hospital readmissions as a measure of quality of health care: advantages and limitations. Arch Intern Med. 2000;160(8):1074–81.
- Gourin CG, Forastiere AA, Sanguineti G, Koch WM, Marur S, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical care. Laryngoscope. 2011;121(1):85–90.
- Jalisi S, Bearelly S, Abdillahi A, Truong MT. Outcomes in head and neck oncologic surgery at academic medical centers in the United States. Laryngoscope. 2013;123(3):689–98.
- Chen AY, Fedewa S, Pavluck A, Ward EM. Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer. Cancer. 2010;116(20):4744–52.

- Gourin CG, Podolsky RH. Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope. 2006;116(7):1093–106.
- 21. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest. 1992;101(6):1481–3.
- Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the national VA surgical risk study. Arch Surg. 1999;134(1):36–42.
- 23. Phillips A, Shaper AG, Whincup PH. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet. 1989;2(8677):1434–6.
- Sganga G, Siegel JH, Brown G, Coleman B, Wiles CE 3, Belzberg H, et al. Reprioritization of hepatic plasma protein release in trauma and sepsis. Arch Surg. 1985;120(2):187–99.
- 25. Dowd PS, Heatley RV. The influence of undernutrition on immunity. Clin Sci. 1984;66(3):241–8.
- Worku B, Tortolani AJ, Gulkarov I, Isom OW, Klein I. Preoperative hypothyroidism is a risk factor for postoperative atrial fibrillation in cardiac surgical patients. J Card Surg. 2015;30(4):307–12.
- 27. Walid MS, Zaytseva N. How does chronic endocrine disease affect cost in spine surgery? World Neurosurg. 2010;73(5):578–81.
- Wachtel TJ, Derby C, Fulton JP. Predicting the outcome of hospitalization for elderly persons: home versus nursing home. South Med J. 1984;77(10):1283–5.
- Merkow RP, Ju MH, Chung JW, Hall BL, Cohen ME, Williams MV, et al. Underlying reasons associated with hospital readmission following surgery in the United States. JAMA. 2015;313(5):483–95.
- AlDardeir N, Alzhrani G, Alqutub A, Kabli R, Sait D, Alsaeed R, et al. Rates and causes of readmission within 60 days following hysterectomy in a Tertiary Care Center in Saudi Arabia. Cureus. 2023;15(3):e36500.
- Castro MA, Dedivitis RA, Ribeiro KC. Comorbidity measurement in patients with laryngeal squamous cell carcinoma. ORL. 2007;69(3):146–52.
- 32. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. J Natl Cancer Inst. 2007;99(10):777–89.
- 33. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48(11):3282–7.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

# Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$  thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

